1. Home
  2. DOUG vs IPHA Comparison

DOUG vs IPHA Comparison

Compare DOUG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Douglas Elliman Inc.

DOUG

Douglas Elliman Inc.

HOLD

Current Price

$1.82

Market Cap

162.3M

Sector

Real Estate

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.91

Market Cap

189.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOUG
IPHA
Founded
1911
1999
Country
United States
France
Employees
N/A
163
Industry
Building operators
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
162.3M
189.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
DOUG
IPHA
Price
$1.82
$1.91
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
471.4K
128.4K
Earning Date
05-05-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
118.68
N/A
EPS
N/A
N/A
Revenue
$955,578,000.00
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.53
$1.18
52 Week High
$3.19
$2.63

Technical Indicators

Market Signals
Indicator
DOUG
IPHA
Relative Strength Index (RSI) 48.97 54.47
Support Level $1.55 $1.72
Resistance Level $1.84 $2.34
Average True Range (ATR) 0.13 0.21
MACD -0.01 0.05
Stochastic Oscillator 40.98 40.77

Price Performance

Historical Comparison
DOUG
IPHA

About DOUG Douglas Elliman Inc.

Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: